Literature DB >> 23138565

Bringing pharmacogenetics to the bedside.

Ankur Gupta.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23138565     DOI： 10.1007/s00228-012-1444-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  3 in total

1.  Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Authors:  Jason D Roberts; George A Wells; Michel R Le May; Marino Labinaz; Chris Glover; Michael Froeschl; Alexander Dick; Jean-Francois Marquis; Edward O'Brien; Sandro Goncalves; Irena Druce; Alexandre Stewart; Michael H Gollob; Derek Y F So
Journal:  Lancet       Date:  2012-03-29       Impact factor: 79.321

2.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Authors:  Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

3.  Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.

Authors:  K Subraja; S A Dkhar; R Priyadharsini; B K Ravindra; D G Shewade; S Satheesh; M G Sridhar; S K Narayan; C Adithan
Journal:  Eur J Clin Pharmacol       Date:  2012-09-06       Impact factor: 2.953
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.